Expertise in
7
conditions

Katja Deterding

Carl Neuberg Str. 1, 
Hannover, NI, DE 
Expertise in
7
conditions
Carl Neuberg Str. 1, 
Hannover, NI, DE 

Overview

Katja Deterding practices practicing medicine in Hannover, Germany.

Ms. Deterding is highly rated in 7 conditions, according to our data. Her clinical expertise encompasses Hepatitis D, Hepatitis, Hepatitis C, and Hepatitis B.

She is actively involved in clinical research, co-authoring 88 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Carl Neuberg Str. 1, Hannover, NI 30625, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study
Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study
Enrollment Status: Completed
Publish Date: July 06, 2021
Intervention Type: Drug
Study Drug: Sofosbuvir+Velpatasvir
Study Phase: Phase 2
View 1 Less Clinical Trial

88 Total Publications

Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver Cirrhosis.
Acute HEV Infection Is a Relevant Cause of Decompensation and ACLF in Patients With Liver Cirrhosis.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: September 22, 2025

Frequently Asked Questions about Katja Deterding

Is Katja Deterding a top-rated expert for Hepatitis D?

MediFind is an objective health platform that identifies experts based on real-world data. Katja Deterding is classified as an Elite expert for Hepatitis D, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Katja Deterding participate in research or clinical trials?

Yes. Katja Deterding has published 88 articles and abstracts on conditions like Hepatitis D. You can view a list of Katja Deterding's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Deterding's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile